Hyoscine butylbromide Kalceks 20 mg/ml šķīdums injekcijām Latvia - Tiếng Latvia - Zāļu valsts aģentūra

hyoscine butylbromide kalceks 20 mg/ml šķīdums injekcijām

kalceks, a/s, latvia - hioscīna butilbromīds - Šķīdums injekcijām - 20 mg/ml

Bridion Liên Minh Châu Âu - Tiếng Latvia - EMA (European Medicines Agency)

bridion

merck sharp & dohme b.v. - sugammadex - neiromuskulārā blokāde - visi pārējie terapeitiskie produkti - rokuronija vai vekuronija izraisītas neiromuskulārās blokādes atsākšana. par peadiatric iedzīvotāju skaits: sugammadex ir tikai ieteicama regulāra maiņa rocuronium izraisītu blokādes bērniem un pusaudžiem.

Rocuronium bromide Kalceks 10 mg/ml šķīdums injekcijām/infūzijām Latvia - Tiếng Latvia - Zāļu valsts aģentūra

rocuronium bromide kalceks 10 mg/ml šķīdums injekcijām/infūzijām

kalceks, a/s, latvia - rokuronija bromīds - Šķīdums injekcijām/infūzijām - 10 mg/ml

Sugammadex Amomed Liên Minh Châu Âu - Tiếng Latvia - EMA (European Medicines Agency)

sugammadex amomed

aop orphan pharmaceuticals gmbh - sugammadex sodium - neiromuskulārā blokāde - visi pārējie terapeitiskie produkti - rokuronija vai vekuronija izraisītas neiromuskulārās blokādes atsākšana. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Sugammadex Mylan Liên Minh Châu Âu - Tiếng Latvia - EMA (European Medicines Agency)

sugammadex mylan

mylan ireland limited - sugammadex sodium - neiromuskulārā blokāde - visi pārējie terapeitiskie produkti - reversal of neuromuscular blockade induced by   rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Thalidomide BMS (previously Thalidomide Celgene) Liên Minh Châu Âu - Tiếng Latvia - EMA (European Medicines Agency)

thalidomide bms (previously thalidomide celgene)

bristol-myers squibb pharma eeig - talidomīds - multiple mieloma - imūnsupresanti - thalidomide bms in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. thalidomide bms is prescribed and dispensed according to the thalidomide celgene pregnancy prevention programme (see section 4.

Sugammadex Fresenius Kabi Liên Minh Châu Âu - Tiếng Latvia - EMA (European Medicines Agency)

sugammadex fresenius kabi

fresenius kabi deutschland gmbh - sugammadex sodium - neiromuskulārā blokāde - visi pārējie terapeitiskie produkti - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Thalidomide Lipomed Liên Minh Châu Âu - Tiếng Latvia - EMA (European Medicines Agency)

thalidomide lipomed

lipomed gmbh - talidomīds - multiple mieloma - imūnsupresanti - thalidomide lipomed in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy. thalidomide lipomed is prescribed and dispensed in accordance with the thalidomide lipomed pregnancy prevention programme (see section 4.

Sugammadex Piramal Liên Minh Châu Âu - Tiếng Latvia - EMA (European Medicines Agency)

sugammadex piramal

piramal critical care b.v. - sugammadex sodium - neiromuskulārā blokāde - sugammadex - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.

Sugammadex Adroiq Liên Minh Châu Âu - Tiếng Latvia - EMA (European Medicines Agency)

sugammadex adroiq

extrovis eu ltd. - sugammadex sodium - neiromuskulārā blokāde - visi pārējie terapeitiskie produkti - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.